Natco Pharma Ltd on Friday reported a 57 per cent decline in consolidated net profit at Rs 206.5 crore in the first quarter ended June 2026, hit by lower sales of its generic cancer treatment drug lenalidomide.
The company had posted a consolidated net profit of Rs 480.3 crore in the corresponding quarter last fiscal, Natco Pharma said in a regulatory filing.